Crinetics Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (the "Shares") (CRNX) Institutional Ownership

13F Institutional Holders and Ownership History from Q3 2018 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.001 per share (the "Shares")
Symbol
CRNX on Nasdaq
Shares outstanding
94,401,153
Price per share
$55.69
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
111,610,559
Total reported value
$5,195,621,593
% of total 13F portfolios
0%
Share change
+4,023,599
Value change
+$195,151,674
Number of holders
239
Price from insider filings
$55.69
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Crinetics Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (the "Shares") (CRNX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
FMR LLC 15% +46% $466,033,211 +$144,432,819 13,957,269 +45% FMR LLC 31 Mar 2025
VANGUARD GROUP INC 10% +2% $310,914,324 +$7,419,559 9,311,600 +2.4% The Vanguard Group 31 Mar 2025
WELLINGTON MANAGEMENT GROUP LLP 8.9% +45% $349,109,925 +$107,235,547 8,381,991 +44% Wellington Management Group LLP 30 Sep 2025
Farallon Capital Partners, L.P. 8.5% +42% $373,521,762 +$111,673,450 8,024,098 +43% Dapice Joshua J. 31 Dec 2025

As of 31 Dec 2025, 239 institutional investors reported holding 111,610,559 shares of Crinetics Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (the "Shares") (CRNX). This represents 118% of the company’s total 94,401,153 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Crinetics Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (the "Shares") (CRNX) together control 97% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
FMR LLC 15% 14,293,775 +0.75% 0.03% $665,375,245
VANGUARD GROUP INC 9.7% 9,135,504 -0.38% 0.01% $425,257,712
WELLINGTON MANAGEMENT GROUP LLP 8.5% 8,037,889 -4.1% 0.07% $374,163,733
BlackRock, Inc. 8.5% 7,988,548 +5.3% 0.01% $371,866,926
FARALLON CAPITAL MANAGEMENT LLC 7.3% 6,933,098 +20% 1.9% $322,735,712
Driehaus Capital Management LLC 6.8% 6,387,740 -1.4% 2% $297,349,297
PRICE T ROWE ASSOCIATES INC /MD/ 5.5% 5,224,387 -1.5% 0.03% $243,196,000
JANUS HENDERSON GROUP PLC 4.7% 4,440,691 +15% 0.09% $206,603,847
EcoR1 Capital, LLC 4.5% 4,288,120 0% 9.1% $199,611,986
Point72 Asset Management, L.P. 2.5% 2,337,034 +17% 0.17% $108,788,933
GEODE CAPITAL MANAGEMENT, LLC 2.4% 2,242,631 -1.6% 0.01% $104,411,409
Paradigm Biocapital Advisors LP 2.3% 2,210,774 -13% 2.8% $102,911,530
STATE STREET CORP 2.3% 2,161,378 -2.1% 0% $100,612,146
BAKER BROS. ADVISORS LP 1.7% 1,648,869 +489% 0.45% $76,754,852
NOVO HOLDINGS A/S 1.7% 1,625,000 0% 5.9% $75,643,750
Pictet Asset Management Holding SA 1.7% 1,560,300 +6.5% 0.07% $72,631,965
Siren, L.L.C. 1.6% 1,507,636 -11% 2.1% $70,180,456
GW&K Investment Management, LLC 1.6% 1,476,325 +74% 0.59% $68,723,000
RTW INVESTMENTS, LP 1.4% 1,351,326 +55% 0.63% $62,904,225
BNP PARIBAS ASSET MANAGEMENT Holding S.A. 1.4% 1,327,382 +59% 0.07% $61,789,000
JENNISON ASSOCIATES LLC 1.4% 1,281,601 -37% 0.04% $59,658,525
First Light Asset Management, LLC 1.3% 1,194,263 +27% 4.3% $55,592,943
JPMORGAN CHASE & CO 1.2% 1,154,710 -8.3% 0% $53,751,750
AMERICAN CENTURY COMPANIES INC 1.1% 1,068,878 -5.7% 0.03% $49,756,351
ORBIMED ADVISORS LLC 1.1% 999,000 -9.1% 0.99% $46,503,450

Institutional Holders of Crinetics Pharmaceuticals, Inc. - Common Stock, par value $0.001 per share (the "Shares") (CRNX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 111,610,559 $5,195,621,593 +$195,151,674 $46.55 239
2025 Q3 107,709,232 $4,486,288,734 +$149,976,766 $41.65 225
2025 Q2 104,559,713 $3,007,383,972 +$75,026,414 $28.76 220
2025 Q1 101,790,412 $3,418,305,905 +$9,856,311 $33.54 225
2024 Q4 99,690,161 $5,097,004,672 +$758,098,969 $51.13 245
2024 Q3 84,525,573 $4,321,960,073 +$33,724,194 $51.10 233
2024 Q2 82,487,807 $3,694,594,767 +$92,152,096 $44.79 232
2024 Q1 80,384,076 $3,762,661,947 +$486,785,470 $46.81 201
2023 Q4 70,656,199 $2,513,959,167 +$68,274,571 $35.58 180
2023 Q3 68,535,017 $2,038,114,354 +$440,832,585 $29.74 171
2023 Q2 54,057,835 $974,084,774 -$11,795,159 $18.02 138
2023 Q1 55,062,782 $884,310,368 +$2,280,401 $16.06 127
2022 Q4 54,817,398 $1,003,122,430 -$14,306,281 $18.30 121
2022 Q3 51,456,378 $1,010,816,996 +$16,147,822 $19.64 118
2022 Q2 50,645,843 $944,532,132 +$94,595,270 $18.65 109
2022 Q1 45,482,453 $997,426,956 -$15,117,112 $21.95 114
2021 Q4 44,273,322 $1,256,550,441 +$251,517,738 $28.41 114
2021 Q3 33,632,624 $708,150,662 +$17,177,215 $21.05 91
2021 Q2 32,726,853 $616,933,642 +$42,446,903 $18.85 81
2021 Q1 30,730,499 $465,273,247 +$5,520,857 $15.28 78
2020 Q4 30,426,213 $429,299,885 -$4,592,533 $14.11 84
2020 Q3 30,337,604 $475,397,972 -$19,900,117 $15.67 70
2020 Q2 31,451,376 $546,085,663 +$188,712,886 $17.52 79
2020 Q1 20,679,487 $303,862,789 +$45,411,611 $14.70 55
2019 Q4 17,526,211 $439,727,847 -$5,476,519 $25.09 58
2019 Q3 15,234,699 $229,128,583 -$94,271,503 $15.04 60
2019 Q2 18,931,321 $473,283,223 +$31,131,935 $25.00 63
2019 Q1 17,737,322 $403,697,060 +$20,738,652 $22.76 62
2018 Q4 16,786,897 $503,433,000 +$19,006,654 $29.99 50
2018 Q3 16,164,902 $463,124,000 +$463,124,002 $28.65 49